STOCKHOLM, April 06, 2016 /PRNewswire/ --
Medivir AB (Nasdaq Stockholm: MVIR) today informs that preclinical data on MIV-818 will be presented by Medivir at The International Liver Congress™ 2017 of the European Association for the Study of the Liver (EASL) in Amsterdam, on 19-23 April. The poster presentation, abstract SAT-123, is entitled "Liver-targeting with the novel nucleotide prodrug MIV-818 designed for the treatment of liver cancers" and will include data on the anticancer activity and pharmacokinetic profile of MIV-818.
Details of all presentations for The International Liver Congress™ 2017 are available at the website: http://www.easl.eu/.
For further information, please contact:
CSO Medivir AB,
Mobile +46 (0)72-704 3211
CFO Medivir AB,
Mobile: +46 (0) 725-480-580
Medivir develops innovative pharmaceutical products for the treatment of cancer. The company specialises in protease inhibitor research and nucleotide/nucleoside science and conducts research in all stages of the drug development process, from original idea to clinical phase III studies. Its development work is done both in-house and through partnerships.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF)
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/medivir---new-data-on-miv-818-will-be-presented-at-easls-international-liver-congress-2017-300435840.html